TABLE 2.

Mechanism and Research Progress of drugs targeting lipotoxicity and cell death.

Drug name	Drug targets	NCT number	Current research progress	Status	Reference
Ornithine Aspartic Acid	Targeted oxidative stress. Ammonia-lowering action	NCT05042245	Phase Ⅳ	Recruiting	https://clinicaltrials.gov
Resveratrol	Targeted oxidative stress. Regulate Sirtuin-1 autophagy pathway. Reduce ER stress	NCT02030977	Phase Ⅱ/Ⅲ	Completed	Faghihzadeh et al. (2014)
Vitamin E	Targeted oxidative stress. Improve inflammation and fibrosis	NCT01792115	Phase Ⅱ	Completed	Podszun et al. (2020)
Silymarin	Targeted endoplasmic reticulum stress. Improve inflammation and fibrosis	NCT02006498	Phase Ⅱ	Completed	Wah Kheong et al. (2017)
Niacin	Targeted oxidative stress. Improve hepatic steatosis, inflammation and lipid accumulation	NCT04330326	Phase Ⅱ	Unknown	https://clinicaltrials.gov
Anthocyanins	Targeted oxidative stress. Decrease sembp1c. Induced PPARα Activity	NCT01940263	Phase Ⅰ	Completed	Zhang et al. (2015)
Bicyclol	Inhibition of MAPK and NF-κB signal path	-	Preclinical study	Completed	Zhao et al. (2021)
Piceatannol	Targeted oxidative stress. Reduce fat accumulation	-	Preclinical study	Completed	Yang et al. (2020)
Polydatin	Targeted oxidative stress. Improve inflammation and fibrosis	-	Preclinical study	Completed	Li et al. (2018)

PPAR α, peroxisome proliferator-activated receptor α; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κB.